Comparative Pharmacology
Head-to-head clinical analysis: CYLTEZO versus SIMLANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYLTEZO versus SIMLANDI.
CYLTEZO vs SIMLANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.
SIMLANDI (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, thereby reducing inflammatory responses.
Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.
Subcutaneous injection, 40 mg every 2 weeks; may increase to 40 mg weekly if no response within 4 weeks.
None Documented
None Documented
Approximately 14 days (range 10–20 days) following subcutaneous administration; supports every-other-week dosing.
Terminal elimination half-life is approximately 14 days (range 10–20 days) in patients with rheumatoid arthritis; this supports a subcutaneous dosing interval of every other week.
Primarily eliminated via intracellular catabolism; no significant renal or biliary elimination of intact adalimumab.
Adalimumab is eliminated primarily via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion of intact drug is minimal.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor